<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16537">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767909</url>
  </required_header>
  <id_info>
    <org_study_id>ADC-046-INI</org_study_id>
    <nct_id>NCT01767909</nct_id>
  </id_info>
  <brief_title>The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)</brief_title>
  <official_title>Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzheimer's Disease Cooperative Study (ADCS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alzheimer's Disease Cooperative Study (ADCS)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can
      arrest or reverse the disease at its earliest stages. The emotional and financial burden of
      AD to patients, family members, and society is enormous, and is predicted to grow
      exponentially as the median population age increases. Current FDA-approved therapies are
      modestly effective at best. This study will examine a novel therapeutic approach using
      intranasal insulin (INI) that has shown promise in short-term clinical trials. If
      successful, information gained from the study has the potential to move INI forward rapidly
      as a therapy for AD. The study will also provide evidence for the mechanisms through which
      INI may produce benefits by examining key cerebral spinal fluid (CSF) biomarkers and
      hippocampal/entorhinal atrophy. These results will have considerable clinical and scientific
      significance, and provide therapeutically-relevant knowledge about insulin's effects on AD
      pathophysiology. Growing evidence has shown that insulin carries out multiple functions in
      the brain, and that insulin dysregulation may contribute to AD pathogenesis.

      This study will examine the effects of intranasally-administered insulin on cognition,
      entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid (CSF) biomarkers in
      amnestic mild cognitive impairment (aMCI) or mild AD.  It is hypothesized that after 12
      months of treatment with INI compared to placebo, subjects will improve performance on a
      global measure of cognition, on a memory composite and on daily function.  In addition to
      the examination of CSF biomarkers and hippocampal and entorhinal atrophy, the study aims to
      examine whether baseline AD biomarker profile, gender, or Apolipoprotein epsilon 4 (APOE-ε4)
      allele carriage predict treatment response.

      In this study, 240 people with aMCI or AD will be given either INI or placebo for 12 months,
      following an open-label period of 6 months where all participants will be given active drug.
       The study uses insulin as a therapeutic agent and intranasal administration focusing on
      nose to brain transport as a mode of delivery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in global measure of cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12)</measure>
    <time_frame>Baseline, Months 3, 6, 9, 12, and 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.  A higher score indicates more impairment.  Scores from the original portion of the test range from 0 (best) to 70 (worse) and then number of items not recalled ranging from 0-10 is added for a maximum score of 80.  A positive change indicates cognitive worsening.  This study will be using the ADAS-Cog12 version, which includes Delayed Word Recall - a measure of episodic memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Memory Composite as measured by Story Recall and Buschke Selective Reminding Test</measure>
    <time_frame>Baseline, Months 6, 12, and 18</time_frame>
    <safety_issue>No</safety_issue>
    <description>A memory composite measure combines two episodic memory measures, immediate and delayed recall. Story Recall is a test of contextual verbal recall, in which participants listen to a story containing 44 informational bits that is read once. Participants will be asked to recall the story immediately after the reading and after a 20-minute delay. Credit is awarded for each bit recalled verbatim or accurately paraphrased.
The Buschke Selective Reminding Test measures verbal memory through multiple trials of a list learning task. A list of 12 words is audibly presented to the participants, who then recall as many words as possible. On subsequent trials, participants are only told those words they omitted on the previous trial. The procedure continues until the participant recalls all words on two subsequent trials or to the twelfth trial. After a 30-minute delay, participants recall as many items as possible. The number of items recalled after the delay will be summed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in daily functioning as measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI)</measure>
    <time_frame>Baseline, Month 6, 12, and 18</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale (ADCS-ADL) is an activities of daily living questionnaire aimed at detecting functional decline in people with Mild Cognitive Impairment (MCI). In a structured interview format, informants are queried as to whether participants attempted each item in the inventory during the prior 4 weeks and their level of performance. The questions focus predominantly on instrumental activities of daily living scales (e.g. shopping, preparing meals, using household appliances, keeping appointments, reading). The total score can range from 0-54.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from screen in magnetic resonance imaging (MRI)</measure>
    <time_frame>Screen and Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>MRI will be used to assess the effect of treatment on rate of hippocampal and entorhinal atrophy, and conduct exploratory analyses of other brain regions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change over time on CSF Abeta</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change over time on CSF Abeta/tau ratio</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the response to treatment of INI based on baseline AD biomarker profile</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the response to treatment of INI based on gender</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the response to treatment of INI based on APOE-ε4 genotype</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine whether further improvement occurs after 18 months of treatment</measure>
    <time_frame>After 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Amnestic Mild Cognitive Impairment</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Insulin (Humulin® R U-100)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months.  A 6-month open label period will follow in which all participants will receive INI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months.  A 6-month open label period will follow in which all participants will receive INI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (Humulin® R U-100)</intervention_name>
    <description>20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally.  The device used to administer insulin releases a metered dose into a chamber covering the participant's nose.  The insulin is then inhaled by breathing evenly over a specified period.</description>
    <arm_group_label>Insulin (Humulin® R U-100)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally.  The device used to administer placebo releases a metered dose into a chamber covering the participant's nose.  The placebo is then inhaled by breathing evenly over a specified period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fluent in English or Spanish

          -  Diagnosis of aMCI by Petersen criteria or probable AD by National Institute of
             Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related
             Disorders Association (NINCDS-ADRDA) criteria

          -  Mini Mental State Examination (MMSE) score at screening is greater than or equal to
             20

          -  Clinical Dementia Rating is 0.5-1 at screening

          -  Logical Memory is less than or equal to 8 for 16 or more years of education, less
             than or equal to 4 for 8-15 years of education, less than or equal to 2 for 0-7 years
             of education. Scores measured at screening on Delayed Paragraph Recall (Paragraph A
             only) from the Wechsler Memory Scale-Revised

          -  Able to complete baseline assessments

          -  Modified Hachinski score of less than or equal to 4

          -  A study partner able to accompany the participant to most visits and answer questions
             about the participant

          -  The study partner must have direct contact with the participant more than 2 days per
             week (minimum of 10 hours per week) and provide supervision of drug administration as
             needed

          -  Stable medical condition for 3 months prior to screening visit

          -  Stable medications for 4 weeks prior to the screening and baseline visits

          -  Stable use of permitted medications

          -  At least six years of education or work history

          -  Clinical laboratory values must be within normal limits or, if abnormal, must be
             judged to be clinically insignificant by the investigator

          -  Visual and auditory acuity adequate for neuropsychological testing

        Exclusion Criteria:

          -  A diagnosis of dementia other than probable AD

          -  Probable AD with Down syndrome

          -  History of clinically significant stroke

          -  Current evidence or history in past two years of epilepsy, focal brain lesion, head
             injury with loss of consciousness or Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (DSM IV) criteria for any major psychiatric disorder
             including psychosis, major depression, bipolar disorder, alcohol or substance abuse

          -  Sensory impairment that would preclude the participant from participating in or
             cooperating with the protocol

          -  Diabetes (type 1 or type II) requiring pharmacologic treatment (including both
             insulin dependent and non-insulin dependent diabetes mellitus)

          -  Current or past use of insulin or any other anti-diabetic medication

          -  Evidence of any significant clinical disorder or laboratory finding that renders the
             participant unsuitable for receiving investigational drug including clinically
             significant or unstable hematologic, hepatic, cardiovascular, pulmonary, endocrine,
             metabolic, renal or other systemic disease or laboratory abnormality.

          -  Active neoplastic disease, history of cancer five years prior to screening (history
             of skin melanoma or stable prostate cancer are not excluded)

          -  History of seizure within the past five years

          -  Pregnancy or possible pregnancy

          -  Contraindications to Lumbar Puncture (LP) procedure: prior lumbosacral spine surgery,
             severe degenerative joint disease or deformity of the spine, platelets is less than
             100,000 or history of bleeding disorder

          -  Use of anticoagulants warfarin (Coumadin) and dabigatran (Pradaxa) due to LP
             requirement

          -  Contraindications for MRI (claustrophobia, craniofacial metal implants of any kind,
             pacemakers)

          -  Residence in a skilled nursing facility at screening

          -  Use of an investigational agent within two months or screening visit

          -  Regular use of narcotics, anticonvulsants, medications with significant
             anticholinergic activity, antiparkinsonian medications or any other exclusionary
             medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Craft, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffree Itrich</last_name>
    <phone>858-246-1317</phone>
    <email>jitrich@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genny Matthews</last_name>
    <phone>858-246-1318</phone>
    <email>gfmatthews@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roy Yaari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marwan Sabbagh, MD, FAAN, CCRI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine McAdams-Ortiz, MSN, RN, A/GNP</last_name>
      <phone>949-824-8726</phone>
    </contact>
    <investigator>
      <last_name>Ruth Mulnard, DNSc, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kacie Smith, BA</last_name>
      <phone>858-246-1303</phone>
      <email>kts001@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Herman</last_name>
      <phone>858-246-1305</phone>
      <email>m1herman@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shauna Yuan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher van Dyck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raymond Scott Turner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Howard University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Obisesan, MD, MPH, FAAFP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neill Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Health Byrd Alzheimer Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Smith, MA, CCRC</last_name>
      <phone>813-974-4355</phone>
      <email>jsmith10@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beth Major, LPN</last_name>
      <phone>813-974-4355</phone>
      <email>bmajor1@health.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amanda Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Pluff</last_name>
      <phone>312-563-4111</phone>
      <email>lindsay_m_pluff@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Stoudemire, MS</last_name>
      <phone>312-942-4824</phone>
      <email>tiffany_stoudemire@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neelum Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Lipowski, BA</last_name>
      <phone>312-503-2486</phone>
      <email>k-lipowski@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mallory Ward, BA</last_name>
      <phone>312-908-9869</phone>
      <email>m-swift@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marek-Marsel Mesulam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martin Farlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Stolyar</last_name>
      <phone>913-945-7676</phone>
      <email>nstolyar@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Becky Bothwell, BS</last_name>
      <phone>913-945-5033</phone>
      <email>rbothwell@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Burns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Nichols, BS</last_name>
      <phone>859-323-3145</phone>
      <email>hdnich2@email.uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kendra Bates</last_name>
      <phone>859-323-5550</phone>
      <email>kendra.bates@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Jicha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Esther Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Scott McGinnis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Knopman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce Haynie, RN, MSN</last_name>
      <phone>314-286-2683</phone>
      <email>hayniej@abraxas.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Millsap, MSN, RN, GNP-BC</last_name>
      <phone>314-286-2363</phone>
      <email>millsapp@abraxas.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David B Carr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hillel Grossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steven Ferris, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Caulder, PhD</last_name>
      <phone>336-713-8847</phone>
      <email>ecaulder@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hector Hernandez-Saucedo, BS</last_name>
      <phone>336-713-3438</phone>
      <email>hehernan@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Baker, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parianne Fatica</last_name>
      <phone>216-464-6474</phone>
      <email>parianne.fatica@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Alan Lerner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Lind, BS</last_name>
      <phone>503-494-9399</phone>
      <email>petriko@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monika Stanko, RN</last_name>
      <phone>503-494-7615</phone>
      <email>stanko@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deniz Erten-Lyons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Astphan, RN</last_name>
      <phone>401-444-2484</phone>
      <email>mastphan@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Kerstin Calia, RN</last_name>
      <phone>401-444-9861</phone>
      <email>kcalia@lifespan.org</email>
    </contact_backup>
    <investigator>
      <last_name>Henry Querfurth, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacobo Mintzer, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Williams, BA</last_name>
      <phone>214-648-9331</phone>
      <email>gloria.williams2@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Rabb</last_name>
      <phone>214-648-9358</phone>
      <email>jackie.rabb@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kyle Womack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Reid, BS</last_name>
      <phone>713-798-4734</phone>
      <email>lindsayr@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Rachelle Doody, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U of WA / VA Puget Sound Alzheimer's Disease Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elaine Peskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nia.nih.gov/alzheimers</url>
    <description>Alzheimer's Disease Education and Referral (ADEAR) Center. The ADEAR Center is a service of the National Institute on Aging (NIA).</description>
  </link>
  <link>
    <url>http://adcs.org</url>
    <description>Alzheimer's Disease Cooperative Study</description>
  </link>
  <reference>
    <citation>Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12.</citation>
    <PMID>21911655</PMID>
  </reference>
  <reference>
    <citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998 Jan;50(1):164-8.</citation>
    <PMID>9443474</PMID>
  </reference>
  <reference>
    <citation>Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008 Feb 5;70(6):440-8. Epub 2007 Oct 17. Erratum in: Neurology. 2008 Sep 9;71(11):866.</citation>
    <PMID>17942819</PMID>
  </reference>
  <reference>
    <citation>Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011 Jan;68(1):51-7. doi: 10.1001/archneurol.2010.225. Epub 2010 Sep 13.</citation>
    <PMID>20837822</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal insulin</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Amnestic mild cognitive impairment</keyword>
  <keyword>Dementia</keyword>
  <keyword>Brain diseases</keyword>
  <keyword>Memory problems</keyword>
  <keyword>Mental disorders</keyword>
  <keyword>Cognitive disorders</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
